130 related articles for article (PubMed ID: 35394061)
1. Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma.
Zhao F; Chen Y; Li SW; Zhang J; Zhang S; Zhao XB; Yang ZJ; Wang B; He QY; Wang LM; Xu L; Liu PN
J Pathol; 2022 Aug; 257(5):620-634. PubMed ID: 35394061
[TBL] [Abstract][Full Text] [Related]
2. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
[TBL] [Abstract][Full Text] [Related]
3. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
4. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
5. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
[TBL] [Abstract][Full Text] [Related]
6. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
Gehlhausen JR; Hawley E; Wahle BM; He Y; Edwards D; Rhodes SD; Lajiness JD; Staser K; Chen S; Yang X; Yuan J; Li X; Jiang L; Smith A; Bessler W; Sandusky G; Stemmer-Rachamimov A; Stuhlmiller TJ; Angus SP; Johnson GL; Nalepa G; Yates CW; Wade Clapp D; Park SJ
Hum Mol Genet; 2019 Feb; 28(4):572-583. PubMed ID: 30335132
[TBL] [Abstract][Full Text] [Related]
7. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Bhattacharyya S; Oblinger JL; Beauchamp RL; Yin Z; Erdin S; Koundinya P; Ware AD; Ferrer M; Jordan JT; Plotkin SR; Xu L; Chang LS; Ramesh V
Neuro Oncol; 2023 Sep; 25(9):1617-1630. PubMed ID: 36806881
[TBL] [Abstract][Full Text] [Related]
8. LiCl Treatment Induces Programmed Cell Death of Schwannoma Cells through AKT- and MTOR-Mediated Necroptosis.
Wang Y; Zhang Q; Wang B; Li P; Liu P
Neurochem Res; 2017 Aug; 42(8):2363-2371. PubMed ID: 28397069
[TBL] [Abstract][Full Text] [Related]
9. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
10. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
Blakeley J
Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
[TBL] [Abstract][Full Text] [Related]
11. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
[TBL] [Abstract][Full Text] [Related]
13. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Wong HK; Lahdenranta J; Kamoun WS; Chan AW; McClatchey AI; Plotkin SR; Jain RK; di Tomaso E
Cancer Res; 2010 May; 70(9):3483-93. PubMed ID: 20406973
[TBL] [Abstract][Full Text] [Related]
15. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
[TBL] [Abstract][Full Text] [Related]
17. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
18. Laryngeal plexiform schwannoma as first symptom in a patient with neurofibromatosis type 2.
Nagato T; Katada A; Yoshizaki T; Kunibe I; Takahara M; Katayama A; Hayashi T; Harabuchi Y
Clin Neurol Neurosurg; 2010 Jul; 112(6):505-8. PubMed ID: 20303213
[TBL] [Abstract][Full Text] [Related]
19. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Ammoun S; Flaiz C; Ristic N; Schuldt J; Hanemann CO
Cancer Res; 2008 Jul; 68(13):5236-45. PubMed ID: 18593924
[TBL] [Abstract][Full Text] [Related]
20. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
